TD Cowen initiated coverage of Benitec Biopharma (BNTC) with a Buy rating and no price target The company’s DNA-directed ‘silence and replace’ platform combines RNAi silencing sequences with replacement genes, the analyst tells investors in a research note. The firm believes Benitec’s lead asset BB-301 for oculopharyngeal muscular dystrophy showed “compelling” Phase 1/2 clinical data, with improving subjective and objective dysphagia measures in three patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTC:
- Innovative Gene Therapy Approach Drives Buy Rating for Benitec Biopharma
- Benitec Biopharma files to sell 900K shares of common stock for holders
- Positive Buy Recommendation for Benitec Biopharma Driven by Promising Clinical Progress and Strong Financial Position
- Benitec Biopharma reports Q3 EPS (24c) vs. (23c) last year